Companies / CYP

CYNATA THERAPEUTICS LIMITED

ASX:CYPPharmaceuticals, Biotechnology & Life Sciences
243.5M shares on issueASX (delayed) · snapshot 11 Sept 2026251.4M fully diluted+3.3% if every option and right converts$0.011price · delayed$2.7Mmarket cap · indicative

Today’s holders own 96.8% of what they think they own, once every option and right converts.

High
Dilution risk

Runway under 2 quarters; share count grew 35% in 24 months; 4 cash raises in 24 months

MinimalVery high
Absolute levels — not a ranking against other companies.
Cash runway-0.4 quarters of funding
Share-count growth (24m)34.7%
Raise cadence (24m)4 cash raises
Options & rights overhang3.3% of shares
In-the-money supply0.0% of shares
Pending proposed issuesopen proposed issue (Appendix 3B)

CYNATA THERAPEUTICS LIMITED's ordinary share count grew 34.7% between September 2024 and May 2026, to 243M shares. The company raised capital four times in the past 24 months for total disclosed proceeds of A$2.7M, most recently a A$1.5M placement in April 2026. Options and rights on issue could convert into 8M new shares, equal to 3.3% of the current share count, with the nearest expiry in November 2027. As of the June 2026 quarter, the company reported an available cash balance of A$-813K, representing approximately -0.4 quarters of funding at its recent spending rate. One proposed securities issue (Appendix 3B) is pending, with an expected issue date in October 2026.

AI-generated summary of this page's cited filings · updated 11 Sept 2026
Get told when this changes
Set up alerts
Daily email alerts cover risk-level moves, new raises, pending proposed issues and option expiries for the companies you follow.
3.3%
Options & rights overhang
0.0%
In-the-money supply
2
Raises · last 12 months
-0.4 qtrs
Cash cover · under 2 quarters

Shares on issue — last 2 years

Ordinary shares on issue
Weekly counts from ASX records. Dots mark cash capital raises. Latest count 243.5M per ASX (delayed) (snapshot 11 Sept 2026).
180M200M220M240MDec 24Oct 25Sept 26Cash raise · 29 Apr 2026Cash raise · 22 Jan 2026Cash raise · 4 June 2025Cash raise · 3 Dec 2024243.5M

Cash runway

-0.4 qtrs
Less than two quarters of funding at the recent spend rate — near-term funding pressure.
$-836k cash after burn from the quarter ended 30 June 2026 · Runway is computed from Appendix 4C/5B filings and announced raise proceeds. Filed with the quarterly report: $897k cash at quarter end (item 4.6), 0.4 qtrs of funding on the company’s own estimate. Our figure above carries the filed quarter-end balance forward at the reported spend rate and adds announced raise proceeds.
Free account
15 quarters on record — Cash runway history
Quarterly cash, net spend and cover trend from every Appendix 4C/5B on record up to 30 June 2026.
Free account: 2 full company unlocks every month, no card.
Create free accountSee plans

Issuance timeline

Latest 5 filings (Appendix 2A quoted issues, 3G unquoted, 3H cancellations)

DateFormSecurityOn issue, per this filingSource
10 Sept 20263H · cancellationCYP : ORDINARY FULLY PAID243.5MAppendix 3H
9 July 20263H · cancellationCYP : ORDINARY FULLY PAID243.5MAppendix 3H
7 May 20262A · quoted issueCYP : ORDINARY FULLY PAID243.5MAppendix 2A
6 Apr 20263H · cancellationCYP : ORDINARY FULLY PAID237.5MAppendix 3H
30 Nov 20253H · cancellationCYP : ORDINARY FULLY PAID237.5MAppendix 3H
Free account
22 filings on record — Full issuance history
Every quoted and unquoted issue and cancellation on record, plus unquoted securities (Appendix 4.2).
Free account: 2 full company unlocks every month, no card.
Create free accountSee plans

Capital raises

4 cash raises in the last 24 months · 2 in the last 12 months

every 5.6 monthsaverage gap between raises
4.5 monthssince the most recent
3 Dec 2024 – 29 Apr 2026first to most recent in this window
$1.5M
Placement
29 Apr 2026 COMPLETE
Free account
4 raises on record — Full raise history
Issue price, shares issued, brokers and stated purpose for every raise on record.
Free account: 2 full company unlocks every month, no card.
Create free accountSee plans

Forward supply

Every dated event on record that could add securities to the register — option expiries to their stated dates and proposed issues over the next 18 months, on one timeline.

Free account
7 dated events on record — Forward supply calendar
Option expiries and proposed issues on one forward timeline, with the securities each could add.
Free account: 2 full company unlocks every month, no card.
Create free accountSee plans

Placement capacity

How much stock a company can place without asking holders. Listing Rule 7.1 allows 15% of ordinary securities in any 12 months, and every Appendix 3B states how much of it an issue uses.

About 78% of the 15% placement capacity left — about 22% used by Appendix 3B filings in the last 12 months (estimate, as at 2026-09-12). Holder-approved issues and any later ratification are not deducted, so the true headroom can be higher.
Free account
Placement capacity — LR 7.1 / 7.1A
The filings behind the figure: every Appendix 3B in the window with what it says was issued under 7.1 and 7.1A, each row linked to its filing, and how many shares are left.
Free account: 2 full company unlocks every month, no card.
Create free accountSee plans

Pending proposed issues

1 proposed issue pending — Appendix 3B lodged, securities not yet issued. New shares from these issues are not in the counts above until quoted.
Paid plan
1 pending issue on record — Pending issue detail
Size, price, fees, broker and placement-capacity usage for each pending issue.
Unlocks on a paid plan
See plans

Options & convertible securities

3.3%
Options & rights overhang · of current shares
0.0%
In-the-money supply · at current price
8.0M
Potential new shares
Nov 2027
Nearest expiry
What a price move would switch on
4.0M8.0M$0.011 now0.25× today ($0.003) — 0 of the priced supply in the money, 0.0% of shares on issue0.5× today ($0.005) — 0 of the priced supply in the money, 0.0% of shares on issue0.75× today ($0.008) — 0 of the priced supply in the money, 0.0% of shares on issue1× today ($0.011) — 0 of the priced supply in the money, 0.0% of shares on issue1.25× today ($0.014) — 0 of the priced supply in the money, 0.0% of shares on issue1.5× today ($0.017) — 0 of the priced supply in the money, 0.0% of shares on issue2× today ($0.022) — 0 of the priced supply in the money, 0.0% of shares on issue3× today ($0.033) — 0 of the priced supply in the money, 0.0% of shares on issue5× today ($0.055) — 0 of the priced supply in the money, 0.0% of shares on issue10× today ($0.110) — 0 of the priced supply in the money, 0.0% of shares on issue0.25×0.5×0.75×now1.25×1.5×2×3×5×10×

At $0.011 today, 0 securities are in the money (0.0% of shares on issue). No price up to ten times today’s switches on any more priced supply.

  • Priced supply in the money at the price on the axis — the curve, and the only thing on it. Ten prices, sampled: between two of them the true figure lies between the two.
  • 8.0M more carries an exercise price above ten times today’s — off the right of this axis, and in every total on this page.
CodeSecurityTypeExercise priceExpiryOn issueSource
CYPAROptionsPrice-triggered$0.5123 Nov 2027300kFiling
CYPASOptionsPrice-triggered$0.1830 June 20282.0MFiling
CYPAUOptionsPrice-triggered$0.2812 Sept 20281.0MFiling
CYPAEOptionsPrice-triggered$0.1820 Nov 20281.9MFiling
CYPAFOptionsPrice-triggered$0.2016 Jan 2029975kFiling
CYPATOptionsPrice-triggered$0.2917 Apr 20291.8MFiling

“Nil” is a stated nil exercise price: nothing is paid to convert. An em dash means the filing names no exercise price at all. Security is read from the filing’s own class description; an em dash there means the description is not one this table labels. One row is one security class, at the number stated in the most recent quotation application that restated it — linked, and dated, in the last column.

Free account
6 option lines on record — In-the-money value & price ladder
What each line is worth in the money today, the price ladder to the next tranche that converts, and the filing description behind every code.
Free account: 2 full company unlocks every month, no card.
Create free accountSee plans

Director dealings

DateDirectorTypeSharesOptionsOtherValueSource
29 Nov 2025Dr Darryl MaherSell117k220k——3Y notice
29 Nov 2025Dr Geoffrey BrookeSell313k2.5M——3Y notice
29 Nov 2025Dr Paul K WottonSell—300k——3Y notice
Free account
13 notices on record — Full dealing history
Every change-of-director's-interest notice on record, with direction and consideration.
Free account: 2 full company unlocks every month, no card.
Create free accountSee plans

Ownership

Free account
Top-20 holders & substantial holder notices
Top-20 register snapshot and substantial-holder movements, each linked to its source notice.
Free account: 2 full company unlocks every month, no card.
Create free account

Latest announcements

10 Sept 2026Notification of cessation of securities - CYP
31 Aug 2026$PAppendix 4E & Preliminary Final Report
25 Aug 2026Proposed issue of securities - CYP
30 July 2026$PJune 2026 Quarterly Activity Report & Appendix 4C
9 July 2026Notification of cessation of securities - CYP
5 July 2026Final Director's Interest Notice
5 July 2026$PBoard, Management Changes, Expenditure Reductions, RDTI Loan
2 July 2026Ceasing to be a substantial holder
1 July 2026Change in substantial holding
29 June 2026Becoming a substantial holder
23 June 2026Ceasing to be a substantial holder
21 June 2026Investor Webinar
18 June 2026$PReinstatement to Official Quotation
18 June 2026$PCYP-004 Osteoarthritis Trial Results
17 June 2026$PCYP-001 GvHD Trial Primary Evaluation Results
15 June 2026$PSuspension from Quotation
11 June 2026$PTrading Halt
2 June 2026$PEU Positive Opinion on CYP-001 Paediatric Investigation Plan
28 May 2026WHO Selects Proposed INN for Cymerus MSCs
26 May 2026Expected Timing of Clinical Trial Results

Headlines link to the source PDFs on the ASX announcements platform. Data as of 12 Sept 2026.